RAPT Begin Period Cash Flow from 2010 to 2024
| RAPT Stock | USD 1.23 0.11 9.82% |
Begin Period Cash Flow | First Reported 2018-03-31 | Previous Quarter 45.3 M | Current Value 37.1 M | Quarterly Volatility 18.6 M |
Check RAPT Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RAPT Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 952.3 K, Interest Expense of 1.3 M or Selling General Administrative of 14.6 M, as well as many indicators such as Price To Sales Ratio of 208, Dividend Yield of 0.0 or PTB Ratio of 6.8. RAPT financial statements analysis is a perfect complement when working with RAPT Therapeutics Valuation or Volatility modules.
RAPT | Begin Period Cash Flow |
Latest RAPT Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of RAPT Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. RAPT Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in RAPT Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
RAPT Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 45,247,579 | |
| Geometric Mean | 43,521,801 | |
| Coefficient Of Variation | 28.68 | |
| Mean Deviation | 7,502,751 | |
| Median | 45,662,000 | |
| Standard Deviation | 12,976,683 | |
| Sample Variance | 168.4T | |
| Range | 53.4M | |
| R-Value | (0.20) | |
| Mean Square Error | 174.3T | |
| R-Squared | 0.04 | |
| Significance | 0.48 | |
| Slope | (571,394) | |
| Total Sum of Squares | 2357.5T |
RAPT Begin Period Cash Flow History
About RAPT Therapeutics Financial Statements
RAPT Therapeutics shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although RAPT Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in RAPT Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on RAPT Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 38.9 M | 36.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.